From microbes to molecules: mechanistic insights into metabolite-mediated gut inflammation

Abstract

Microbial metabolites are now recognized as central mediators of host–microbe communication that shape intestinal immune homeostasis and influence the development of inflammatory gastrointestinal diseases. The objective of this review is to synthesize current mechanistic evidence on how microbiota-derived metabolites regulate epithelial and immune functions in the gut, with a focus on metabolite-driven inflammatory pathways. In the healthy intestine, short-chain fatty acids (SCFAs), indole derivatives, secondary bile acids, and polyamines support epithelial integrity, regulate mucosal immunity, and maintain metabolic balance. SCFAs, particularly butyrate, attenuate inflammation by serving as an energy source for colonocytes, inhibiting histone deacetylases, activating G protein-coupled receptors (GPCRs; GPR41, GPR43, GPR109A), and reinforcing epithelial barrier function. In parallel, microbial tryptophan metabolites such as indole-3-propionic acid and indole-3-aldehyde activate aryl hydrocarbon receptor signaling, promoting IL-22 production, antimicrobial peptide expression, and Th17–Treg balance. In inflammatory bowel disease, dysbiosis disrupts these protective pathways, leading to depletion of SCFA- and indole-producing taxa and accumulation of pro-inflammatory metabolites such as succinate. These metabolic shifts impair epithelial-immune crosstalk, amplify NF-κB-dependent inflammation, and compromise mucosal repair. Therapeutic strategies targeting microbial metabolites, including precision prebiotics, next-generation probiotics, engineered microbial consortia, and postbiotics, show translational promise. However, their clinical application remains constrained by interindividual variability, incomplete causal resolution, and challenges in targeted delivery. Integrative multi-omics approaches and mechanistically informed models are therefore essential to advance metabolite-based diagnostics and therapies for gut inflammation.

Keywords

inflammation / host–microbe interaction / tryptophan metabolism / serotonin / kynurenine

References

[1] Iyer N, Corr SC. Gut Microbial Metabolite-Mediated Regulation of the Intestinal Barrier in the Pathogenesis of Inflammatory Bowel Disease. Nutrients. 2021; 13: 4259.

[2] Zeng L, Qian Y, Cui X, Zhao J, Ning Z, Cha J, et al. Immunomodulatory role of gut microbial metabolites: mechanistic insights and therapeutic frontiers. Front Microbiol. 2025; 16: 1675065.

[3] Ney LM, Wipplinger M, Grossmann M, Engert N, Wegner VD, Mosig AS. Short chain fatty acids: key regulators of the local and systemic immune response in inflammatory diseases and infections. Open Biol. 2023; 13:230014.

[4] Michaudel C, Danne C, Agus A, Magniez A, Aucouturier A, Spatz M, et al. Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases. Gut. 2023; 72: 1296-307.

[5] Pace F, Rudolph SE, Chen Y, Bao B, Kaplan DL, Watnick PI. The Short-Chain Fatty Acids Propionate and Butyrate Augment Adherent-Invasive Escherichia coli Virulence but Repress Inflammation in a Human Intestinal Enteroid Model of Infection. Microbiol Spectr. 2021; 9: e0136921.

[6] Gao J, Xu K, Liu H, Liu G, Bai M, Peng C, et al. Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism. Front Cell Infect Microbiol. 2018; 8: 13.

[7] Kang H, Chen Z, Wang B, Chen Z. The AhR/IL-22 axis in chronic gut inflammation: unraveling mechanisms and therapeutic prospects. Front Immunol. 2025; 16: 1668173.

[8] Riazati N, Kable ME, Newman JW, Adkins Y, Freytag T, Jiang X, et al. Associations of microbial and indoleamine-2,3-dioxygenase-derived tryptophan metabolites with immune activation in healthy adults. Front Immunol. 2022; 13: 917966.

[9] Zhao M, Zhou C, Wang D, Wu Q, Feng B. Succinate’s Dual Roles in Inflammatory Bowel Disease: A Narrative Review of Microbiota-Metabolism-Immune Crosstalk and Therapeutic Implications. J Inflamm Res. 2025; 18: 15017-32.

[10] Chulenbayeva L, Jarmukhanov Z, Kaliyekova K, Kozhakhmetov S, Kushugulova A. Quantitative Alterations in Short-Chain Fatty Acids in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Biomolecules. 2025; 15: 1017.

[11] Di Vincenzo F, Del Gaudio A, Petito V, Lopetuso LR, Scaldaferri F. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med. 2024; 19: 275-93.

[12] Fusco W, Lorenzo MB, Cintoni M, Porcari S, Rinninella E, Kaitsas F, et al. Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota. Nutrients. 2023; 15: 2211.

[13] Singh V, Lee G, Son H, Koh H, Kim ES, Unno T, et al. Butyrate producers, “The Sentinel of Gut”: Their intestinal significance with and beyond butyrate, and prospective use as microbial therapeutics. Front Microbiol. 2023; 13: 1103836.

[14] Uhlig F, Hyland NP. Making Sense of Quorum Sensing at the Intestinal Mucosal Interface. Cells. 2022; 11: 1734.

[15] Kiran NS, Chatterjee A, Yashaswini C, Deshmukh R, Alsaidan OA, Bhattacharya S, et al. The gastrointestinal mycobiome in inflammation and cancer: unraveling fungal dysbiosis, pathogenesis, and therapeutic potential. Med Oncol. 2025; 42: 195.

[16] Kullberg RFJ, van Linge CCA, Haak BW, Paul PS, Butler JM, Wolff N, et al. Effect of the gut microbiota-derived tryptophan metabolite indole-3-acetic acid in pneumonia. Nat Commun. 2025; 16: 8565.

[17] Šarenac TM, Mikov M. Bile Acid Synthesis: From Nature to the Chemical Modification and Synthesis and Their Applications as Drugs and Nutrients. Front Pharmacol. 2018; 9: 939.

[18] Mazuy C, Helleboid A, Staels B, Lefebvre P. Nuclear bile acid signaling through the farnesoid X receptor. Cell Mol Life Sci. 2015; 72: 1631-50.

[19] Kurhaluk N, Kołodziejska R, Kamiński P, Tkaczenko H. Integrative Neuroimmune Role of the Parasympathetic Nervous System, Vagus Nerve and Gut Microbiota in Stress Modulation: A Narrative Review. Int J Mol Sci. 2025; 26: 11706.

[20] Wuputra K, Ku CC, Hsu WH, Hsieh TJ, Tsai YC, Chen CY, et al. New insights into coordinated regulation of AHR promoter transcription; molecular mechanisms and therapeutic targets. Int J Biol Sci. 2025; 21: 4504-28.

[21] Sivaprakasam S, Bhutia YD, Yang S, Ganapathy V. Short-Chain Fatty Acid Transporters: Role in Colonic Homeostasis. Compr Physiol. 2017; 8: 299-314.

[22] Hamer HM, Jonkers DM, Bast A, Vanhoutvin SA, Fischer MA, Kodde A, et al. Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin Nutr. 2009; 28: 88-93.

[23] Morais LH, Stiles L, Freeman M, Oguienko AD, Hoang JD, Ji J, et al. The gut microbiome promotes mitochondrial respiration in the brain of a Parkinson's disease mouse model. NPJ Parkinsons Dis. 2025; 11: 301.

[24] Gasaly N, Hermoso MA, Gotteland M. Butyrate and the Fine-Tuning of Colonic Homeostasis: Implication for Inflammatory Bowel Diseases. Int J Mol Sci. 2021; 22: 3061.

[25] Salvi PS, Cowles RA. Butyrate and the Intestinal Epithelium: Modulation of Proliferation and Inflammation in Homeostasis and Disease. Cells. 2021; 10: 1775.

[26] Elce A, Amato F, Zarrilli F, Calignano A, Troncone R, Castaldo G, et al. Butyrate modulating effects on pro-inflammatory pathways in human intestinal epithelial cells. Benef Microbes. 2017; 8: 841-7.

[27] Silva YP, Bernardi A, Frozza RL. The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication. Front Endocrinol (Lausanne). 2020; 11: 25.

[28] Du Y, He C, An Y, Huang Y, Zhang H, Fu W, et al. The Role of Short Chain Fatty Acids in Inflammation and Body Health. Int J Mol Sci. 2024; 25: 7379.

[29] Huang S, Gao Y, Wang Z, Yang X, Wang J, Zheng N. Anti-inflammatory actions of acetate, propionate, and butyrate in fetal mouse jejunum cultures ex vivo and immature small intestinal cells in vitro. Food Sci Nutr. 2022; 10: 564-76.

[30] Jangi S, Moyer J, Sandlow S, Fu M, Chen H, Shum A, et al. Microbial butyrate capacity is reduced in inflamed mucosa in patients with ulcerative colitis. Sci Rep. 2024; 14: 3479.

[31] Zhang Z, Zhang H, Chen T, Shi L, Wang D, Tang D. Regulatory role of short-chain fatty acids in inflammatory bowel disease. Cell Commun Signal. 2022; 20: 64.

[32] Li X, Zhang B, Hu Y, Zhao Y. New Insights Into Gut-Bacteria-Derived Indole and Its Derivatives in Intestinal and Liver Diseases. Front Pharmacol. 2021; 12: 769501.

[33] Xue C, Li G, Zheng Q, Gu X, Shi Q, Su Y, et al. Tryptophan metabolism in health and disease. Cell Metab. 2023; 35: 1304-26.

[34] Ren T, Li D, Sun F, Pan L, Wang A, Li X, et al. Indole Propionic Acid Regulates Gut Immunity: Mechanisms of Metabolite-Driven Immunomodulation and Barrier Integrity. J Microbiol Biotechnol. 2025; 35: e2503045.

[35] Sinha AK, Laursen MF, Brinck JE, Rybtke ML, Hjørne AP, Procházková N, et al. Dietary fibre directs microbial tryptophan metabolism via metabolic interactions in the gut microbiota. Nat Microbiol. 2024; 9: 1964-78.

[36] D’Onofrio F, Renga G, Puccetti M, Pariano M, Bellet MM, Santarelli I, et al. Indole-3-Carboxaldehyde Restores Gut Mucosal Integrity and Protects from Liver Fibrosis in Murine Sclerosing Cholangitis. Cells. 2021; 10: 1622.

[37] Li Q, de Oliveira Formiga R, Puchois V, Creusot L, Ahmad AH, Amouyal S, et al. Microbial metabolite indole-3-propionic acid drives mitochondrial respiration in CD4⁺ T cells to confer protection against intestinal inflammation. Nat Metab. 2025; 7: 2510-30.

[38] Mangoni AA, Zinellu A. A systematic review and meta-analysis of the kynurenine pathway of tryptophan metabolism in rheumatic diseases. Front Immunol. 2023; 14: 1257159.

[39] Proietti E, Pauwels RWM, de Vries AC, Orecchini E, Volpi C, Orabona C, et al. Modulation of Indoleamine 2,3-Dioxygenase 1 During Inflammatory Bowel Disease Activity in Humans and Mice. Int J Tryptophan Res. 2023; 16: 11786469231153109.

[40] Lai W, Huang Z, Li S, Li XG, Luo D. Kynurenine pathway metabolites modulated the comorbidity of IBD and depressive symptoms through the immune response. Int Immunopharmacol. 2023; 117: 109840.

[41] Liu N, Sun S, Wang P, Sun Y, Hu Q, Wang X. The Mechanism of Secretion and Metabolism of Gut-Derived 5-Hydroxytryptamine. Int J Mol Sci. 2021; 22: 7931.

[42] Kwon YH, Wang H, Denou E, Ghia JE, Rossi L, Fontes ME, et al. Modulation of Gut Microbiota Composition by Serotonin Signaling Influences Intestinal Immune Response and Susceptibility to Colitis. Cell Mol Gastroenterol Hepatol. 2019; 7: 709-28.

[43] Spencer NJ, Keating DJ. Role of 5-HT in the enteric nervous system and enteroendocrine cells. Br J Pharmacol. 2025; 182: 471-83.

[44] Tanaka M, Tóth F, Polyák H, Szabó Á, Mándi Y, Vécsei L. Immune Influencers in Action: Metabolites and Enzymes of the Tryptophan-Kynurenine Metabolic Pathway. Biomedicines. 2021; 9: 734.

[45] Costantini C, Bellet MM, Renga G, Stincardini C, Borghi M, Pariano M, et al. Tryptophan Co-Metabolism at the Host-Pathogen Interface. Front Immunol. 2020; 11: 67.

[46] Ma N, He T, Johnston LJ, Ma X. Host-microbiome interactions: the aryl hydrocarbon receptor as a critical node in tryptophan metabolites to brain signaling. Gut Microbes. 2020; 11: 1203-19.

[47] Stone TW, Williams RO. Interactions of IDO and the Kynurenine Pathway with Cell Transduction Systems and Metabolism at the Inflammation-Cancer Interface. Cancers (Basel). 2023; 15: 2895.

[48] Cao Y, Shen J, Ran ZH. Association between Faecalibacterium prausnitzii Reduction and Inflammatory Bowel Disease: A Meta-Analysis and Systematic Review of the Literature. Gastroenterol Res Pract. 2014; 2014: 872725.

[49] Xu HM, Zhao HL, Guo GJ, Xu J, Zhou YL, Huang HL, et al. Characterization of short-chain fatty acids in patients with ulcerative colitis: a meta-analysis. BMC Gastroenterol. 2022; 22: 117.

[50] Dai M, Bu S, Miao Z. Succinate metabolism: underlying biological mechanisms and emerging therapeutic targets in inflammatory bowel disease. Front Immunol. 2025; 16: 1630310.

[51] Upadhyay KG, Desai DC, Ashavaid TF, Dherai AJ. Evaluating the role of kynurenine/tryptophan ratio as an indicator of disease activity in Indian patients with inflammatory bowel disease. A case-control study. Scand J Gastroenterol. 2025; 60: 454-62.

[52] Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020; 17: 223-37.

[53] Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol. 2017; 19: 29-41.

[54] Parada Venegas D, De la Fuente MK, Landskron G, González MJ, Quera R, Dijkstra G, et al. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Front Immunol. 2019; 10: 277.

[55] Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell. 2016; 165: 1332-45.

[56] Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol. 2014; 121: 91-119.

[57] Markowiak-Kopeć P, Śliżewska K. The Effect of Probiotics on the Production of Short-Chain Fatty Acids by Human Intestinal Microbiome. Nutrients. 2020; 12: 1107.

[58] Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngom-Bru C, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med. 2014; 20: 159-66.

[59] Agus A, Planchais J, Sokol H. Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. Cell Host Microbe. 2018; 23: 716-24.

[60] Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Pieraccini G, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity. 2013; 39: 372-85.

[61] Lamas B, Richard ML, Leducq V, Pham HP, Michel ML, Da Costa G, et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med. 2016; 22: 598-605.

[62] Kiran NS, Yashaswini C, Chatterjee A, Prajapati B. Impact of gastrointestinal dysbiosis on tryptophan metabolism and neurological cancer progression. Med Oncol. 2025; 42: 412.

[63] Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012; 13: 465-77.

[64] Mawe GM, Hoffman JM. Serotonin signalling in the gut-functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2013; 10: 473-86.

[65] Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015; 161: 264-76.

[66] Belizário JE, Faintuch J, Garay-Malpartida M. Gut Microbiome Dysbiosis and Immunometabolism: New Frontiers for Treatment of Metabolic Diseases. Mediators Inflamm. 2018; 2018: 2037838.

[67] Sun M, Wu W, Liu Z, Cong Y. Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases. J Gastroenterol. 2017; 52: 1-8.

[68] Tan J, Taitz J, Nanan R, Grau G, Macia L. Dysbiotic Gut Microbiota-Derived Metabolites and Their Role in Non-Communicable Diseases. Int J Mol Sci. 2023; 24: 15256.

[69] Boye TL, Hammerhøj A, Nielsen OH, Wang Y. Metabolomics for enhanced clinical understanding of inflammatory bowel disease. Life Sci. 2024; 359: 123238.

[70] Hughes RL, Alvarado DA, Swanson KS, Holscher HD. The Prebiotic Potential of Inulin-Type Fructans: A Systematic Review. Adv Nutr. 2022; 13: 492-529.

[71] Healey GR, Celiberto LS, Lee SM, Jacobson K. Fiber and Prebiotic Interventions in Pediatric Inflammatory Bowel Disease: What Role Does the Gut Microbiome Play? Nutrients. 2020; 12: 3204.

[72] Whelan K, Alexander M, Gaiani C, Lunken G, Holmes A, Staudacher HM, et al. Design and reporting of prebiotic and probiotic clinical trials in the context of diet and the gut microbiome. Nat Microbiol. 2024; 9: 2785-94.

[73] Oh GM, Moon W, Seo KI, Jung K, Kim JH, Kim SE, et al. Therapeutic Potential of Escherichia coli Nissle 1917 in Clinically Remission-attained Ulcerative Colitis Patients: A Hospital-based Cohort Study. Korean J Gastroenterol. 2021; 77: 12-21.

[74] Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. World J Gastroenterol. 2023; 29: 2078-100.

[75] Vijayaganapathi A, Mohanasrinivasan V. A Review of Next-Generation Probiotics-As a Gateway to Biotherapeutics. Probiotics Antimicrob Proteins. 2025; 17: 1985-97.

[76] Tanaka M, Vécsei L. From Microbial Switches to Metabolic Sensors: Rewiring the Gut-Brain Kynurenine Circuit. Biomedicines. 2025; 13: 2020.

[77] Siddiqui MT, Han Y, Shapiro D, West G, Fiocchi C, Cresci GAM. The Postbiotic Butyrate Mitigates Gut Mucosal Disruption Caused by Acute Ethanol Exposure. Int J Mol Sci. 2024; 25: 1665.

[78] Zou ZP, Zhang XP, Zhang Q, Yin BC, Zhou Y, Ye BC. Genetically engineered bacteria as inflammatory bowel disease therapeutics. Eng Microbiol. 2024; 4: 100167.

[79] Kang M, Choe D, Kim K, Cho BK, Cho S. Synthetic Biology Approaches in The Development of Engineered Therapeutic Microbes. Int J Mol Sci. 2020; 21: 8744.

[80] Xiang X, Zhou Z, Rao X, Jiang XR. Recent advances of engineered bacteria for therapeutic applications. Mol Ther. 2025; 34: 714-33.

[81] Cubillos-Ruiz A, Guo T, Sokolovska A, Miller PF, Collins JJ, Lu TK, et al. Engineering living therapeutics with synthetic biology. Nat Rev Drug Discov. 2021; 20: 941-60.

[82] Charbonneau MR, Isabella VM, Li N, Kurtz CB. Developing a new class of engineered live bacterial therapeutics to treat human diseases. Nat Commun. 2020; 11: 1738.

[83] Sadhu S, Paul T, Yadav N. Therapeutic engineering of the gut microbiome using synthetic biology and metabolic tools: a comprehensive review with E. coli Nissle 1917 as a model case study. Arch Microbiol. 2025; 207: 213.

[84] Ma B, Barathan M, Ng MH, Law JX. Oxidative Stress, Gut Microbiota, and Extracellular Vesicles: Interconnected Pathways and Therapeutic Potentials. Int J Mol Sci. 2025; 26: 3148.

[85] Huang Z, Boekhorst J, Fogliano V, Capuano E, Wells JM. Distinct effects of fiber and colon segment on microbiota-derived indoles and short-chain fatty acids. Food Chem. 2023; 398: 133801.

[86] Hüfner K, Giesinger JM, Gostner JM, Egeter J, Koudouovoh-Tripp P, Vill T, et al. Neurotransmitter Precursor Amino Acid Ratios Show Differential, Inverse Correlations with Depression Severity in the Low and High Depression Score Range. Int J Tryptophan Res. 2021; 14: 11786469211039220.

[87] Long NP, Nghi TD, Kang YP, Anh NH, Kim HM, Park SK, et al. Toward a Standardized Strategy of Clinical Metabolomics for the Advancement of Precision Medicine. Metabolites. 2020; 10: 51.

[88] Guan H, Pu Y, Liu C, Lou T, Tan S, Kong M, et al. Comparison of Fecal Collection Methods on Variation in Gut Metagenomics and Untargeted Metabolomics. mSphere. 2021; 6: e0063621.

[89] Bihan DG, Rydzak T, Wyss M, Pittman K, McCoy KD, Lewis IA. Method for absolute quantification of short chain fatty acids via reverse phase chromatography mass spectrometry. PLoS One. 2022; 17: e0267093.

[90] Liebisch G, Ecker J, Roth S, Schweizer S, Öttl V, Schött HF, et al. Quantification of Fecal Short Chain Fatty Acids by Liquid Chromatography Tandem Mass Spectrometry-Investigation of Pre-Analytic Stability. Biomolecules. 2019; 9: 121.

[91] Muller E, Algavi YM, Borenstein E. The gut microbiome-metabolome dataset collection: a curated resource for integrative meta-analysis. NPJ Biofilms Microbiomes. 2022; 8: 79.

[92] Karu N, Deng L, Slae M, Guo AC, Sajed T, Huynh H, et al. A review on human fecal metabolomics: Methods, applications and the human fecal metabolome database. Anal Chim Acta. 2018; 1030: 1-24.

[93] Sun Y, Wu S, Wu Z, Zhu W, Gao H, Xing J, et al. Instance-based Transfer Learning Enables Cross-Cohort Early Detection of Colorectal Cancer. BioRxiv [Preprint]. 2025 [cited 2025 Jan 12]. Available from: https://www.biorxiv.org/content/10.1101/2025.02.22.639690v2

[94] Gazi MA, Das S, Siddique MA, Alam MA, Fahim SM, Hasan MM, et al. Plasma Kynurenine to Tryptophan Ratio Is Negatively Associated with Linear Growth of Children Living in a Slum of Bangladesh: Results from a Community-Based Intervention Study. Am J Trop Med Hyg. 2020; 104: 766-73.

[95] Erben V, Poschet G, Schrotz-King P, Brenner H. Evaluation of different stool extraction methods for metabolomics measurements in human faecal samples. BMJ Nutr Prev Health. 2021; 4: 374-84.

[96] Smolinska S, Popescu FD, Zemelka-Wiacek M. A Review of the Influence of Prebiotics, Probiotics, Synbiotics, and Postbiotics on the Human Gut Microbiome and Intestinal Integrity. J Clin Med. 2025; 14: 3673.

[97] Ma J, Lyu Y, Liu X, Jia X, Cui F, Wu X, et al. Engineered probiotics. Microb Cell Fact. 2022; 21: 72.

[98] Cruz AK, Alves MA, Andresson T, Bayless AL, Bloodsworth KJ, Bowden JA, et al. Multiplatform metabolomic interlaboratory study of a whole human stool candidate reference material from omnivore and vegan donors. Metabolomics. 2024; 20: 125.